<DOC>
	<DOCNO>NCT00867607</DOCNO>
	<brief_summary>A Double-blind , Vehicle-controlled Study Assess Safety , Tolerability , Efficacy Three Weeks Daily Dermal Application MRX-6 steroid Treatment Mild Moderate Allergic Contact Dermatitis Hand Forearm . Total number patient : 80 .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy 21 Days Dermal Application MRX-6 Mild Moderate Contact Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<mesh_term>Dermatitis , Allergic Contact</mesh_term>
	<criteria>1 . Healthy adult men woman 18 65 year old . 2 . Male nonpregnant female subject agree comply applicable contraceptive requirement protocol . Details potential childbearing status , method regularly exclude pregnancy throughout study acceptable form contraception provide Section 3.4.1 protocol . 3 . Satisfactory medical assessment clinically significant relevant abnormality ( medical history , physical examination , clinical laboratory evaluation [ hematology , biochemistry , urinalysis ] ) determine Principal Investigator , might interfere assessment subject dermatitis assessment safety efficacy Study Drug . 4 . The subject must understand able , willing likely fully comply study procedure restriction . 5 . Subject understand provide write informed consent participate study , accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guideline E6 applicable regulation , complete studyrelated procedure list Section 5.1.1 protocol . 6 . Subject mild moderate bilateral allergic contact dermatitis hand , possibly extend forearm , accord Physicians Visual Assessment describe Section 5.2.1 protocol . Mild moderate disease consider PVA score 10 great 1point difference hand . 7 . Have + reaction Standard European Series patch test kit ( Chemotechnique Diagnostics Products , Malmo , Sweden ) application 2 day , described Section 5.2.2 protocol . 1 . Current recurrent disease could affect action , absorption disposition Study Drug , clinical laboratory assessment . 2 . Have use topical antihistamine past 2 week , topical corticosteroid receive Psoralen plus ultra violet light therapy ( PUVA ) past 4 week , take oral retinoids , corticosteroid past 8 week ( inhale intranasal corticosteroid allow , stable dose ) . 3 . Use prescription OTC medication ( exclude hormonal contraceptive , hormonal replacement therapy , inhale intranasal corticosteroid , oral NSAIDs ) , opinion Principal Investigator , could affect ( improve worsen ) condition study , could affect action , absorption disposition Study Drug , clinical laboratory assessment . 4 . Patients must use another investigational product take part clinical trial within last 30 day prior enrolment . 5 . Female patient pregnant lactating , include female positive pregnancy test screening , must exclude . 6 . The subject know positive hepatitis virus test ( Hepatitis B virus surface antigen hepatitis C virus antibody ) positive human immunodeficiency virus ( HIV ) antibody test . 7 . A history hypersensitivity Study Drugs excipients . 8 . Subject significant dermatological condition affect &gt; 10 % body surface area general medical condition could interfere study evaluation 9 . Subject significant medical condition could compromise immune responsiveness 10 . Subject history alcoholism drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Contact dermatitis</keyword>
	<keyword>Eczema</keyword>
</DOC>